In addition, the univariate analyses showed that the NSCLC patients with mutant FGFR4, LUAD, first-line administration of ICIs, ever smoking, elevated PD-L1 score (≥ 50% percentage), or high TMB (≥ 50th percentage) could benefit from ICIs treatment. This evidence concerns the gene FGFR4 and non-small cell lung carcinoma.